Log in

Relevant bibliographies by topics / Mosapride / Journal articles

To see the other types of publications on this topic, follow the link: Mosapride.

Journal articles on the topic 'Mosapride'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Mosapride.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Mosapride." Reactions Weekly &NA;, no. 1414 (2012): 38. http://dx.doi.org/10.2165/00128415-201214140-00128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Curran, Monique P., and Dean M. Robinson. "Mosapride." Drugs 68, no. 7 (2008): 981–91. http://dx.doi.org/10.2165/00003495-200868070-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wu, Xiao, Cuihong Zheng, Xiaohu Xu, et al. "Electroacupuncture for Functional Constipation: A Multicenter, Randomized, Control Trial." Evidence-Based Complementary and Alternative Medicine 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/1428943.

Full text

Abstract:

Background and Aim. To investigate the efficacy and safety of electroacupuncture (EA) with different current intensities for functional constipation (FC) and to assess whether the effects of EA with different current intensities are superior to the mosapride.Methods. Patients with FC were randomly divided into low current intensity group (LCI), high current intensity group (HCI), and mosapride group (MC). The primary outcome was three or more spontaneous bowel movements (SBMs) per week and an increase of one or more SBMs from baseline during at least 3 of the 4 weeks.Results. The primary outco

APA, Harvard, Vancouver, ISO, and other styles

4

Yoshida, N., S. Kato, and T. Ito. "Mosapride citrate." Drugs of the Future 18, no. 6 (1993): 513. http://dx.doi.org/10.1358/dof.1993.018.06.209477.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Choi, Hyun Seok, Eui Joong Kim, Min Seob Kim, et al. "Effect of Combination Therapy of Oral Famotidine with Mosapride on Intragastric pH and Gastric Emptying in Rats." Korean Journal of Helicobacter and Upper Gastrointestinal Research 21, no. 3 (2021): 220–25. http://dx.doi.org/10.7704/kjhugr.2021.0013.

Full text

Abstract:

Background/Aims: Studies in healthy humans have reported that the addition of mosapride to acid suppressants resulted in higher intragastric pH than acid suppressant administration alone. We investigated the effect of the addition of mosapride to famotidine on the intragastric pH and gastric emptying rate (GER) in rats.Materials and Methods: Sixty male Wistar rats were used in this study. Experimental groups were divided into control, famotidine-only, mosapride-only, and famotidine with mosapride (combination). The first experiment was performed in non-stressed rats. Mosapride was administered

APA, Harvard, Vancouver, ISO, and other styles

6

Nishizawa, Toshihiro, Kiyoto Mori, Shuntaro Yoshida, Hirotoshi Ebinuma, Osamu Toyoshima, and Hidekazu Suzuki. "Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis." Journal of Clinical Medicine 9, no. 9 (2020): 2705. http://dx.doi.org/10.3390/jcm9092705.

Full text

Abstract:

Background and Aim: In gastroesophageal reflux disease (GERD), the additive effect of mosapride to a proton pump inhibitor (PPI) is still controversial. This meta-analysis integrated randomized controlled trials (RCTs) in which mosapride combined with a PPI was compared with a PPI alone in GERD treatment. Methods: RCTs were systematically searched with the PubMed, Cochrane library, Web of Science, and the Igaku-Chuo-Zasshi database. We combined the data from the RCTs with a random effects model, calculated the standardized mean difference (SMD) and pooled the risk difference (RD) with 95% conf

APA, Harvard, Vancouver, ISO, and other styles

7

Wu, Tong, Guanhua Wang, Caihong Shi, et al. "Development and evaluation of orally disintegrating tablets containing the mosapride resin complex." Acta Pharmaceutica 68, no. 2 (2018): 159–70. http://dx.doi.org/10.2478/acph-2018-0017.

Full text

Abstract:

Abstract The purpose of this study was to prepare a mosapride citrate-resin (Amberlite® IRP 88) complex and orally fast-disintegrating tablets of the resin complex. The resinate complex of mosapride-Amberlite® IRP 88, mass ratio 2:1, was prepared in an ethanol-water solution. The effects of alcohol concentration, temperature, and pH of the solution on complex formation were evaluated. The complex physicochemical properties were characterized by differential scanning calorimetry, X-ray diffraction and scanning electron microscopy. Orally disintegrating tablets were prepared by direct compressio

APA, Harvard, Vancouver, ISO, and other styles

8

Kawahara, Isao, Hiroki Kuniyasu, Hiroko Matsuyoshi, et al. "Comparison of effects of a selective 5-HT reuptake inhibitor versus a 5-HT4 receptor agonist on in vivo neurogenesis at the rectal anastomosis in rats." American Journal of Physiology-Gastrointestinal and Liver Physiology 302, no. 6 (2012): G588—G597. http://dx.doi.org/10.1152/ajpgi.00284.2011.

Full text

Abstract:

It was recently reported that activation of enteric neural 5-HT4 receptors (SR4) promotes reconstruction of enteric neural circuit injury in distal gut of guinea pigs and that this reconstruction involves neural stem cells. We aimed to explore a novel approach using a selective serotonin reuptake inhibitor (SSRI), which increases endogenous 5-HT, to repair enteric nerve fiber injury in the rat distal gut. Enteric nerve fiber injury was performed by rectal transection and subsequent end-to-end one-layer anastomosis. The SSRI fluvoxamine maleate (100 μmol/l) was applied locally at the anastomoti

APA, Harvard, Vancouver, ISO, and other styles

9

Lian, Xiaofang, Yiran Li, Limin Zuo, et al. "Comparison and Determination of the Content of Mosapride Citrate by Different qNMR Methods." International Journal of Molecular Sciences 25, no. 19 (2024): 10442. http://dx.doi.org/10.3390/ijms251910442.

Full text

Abstract:

As a salt-type compound, mosapride citrate’s metabolism and side effects are correlated with its salt-forming ratio. Several techniques were developed in this work to compare various quantitative nuclear magnetic resonance (qNMR) methodologies and to quantitatively examine the content of raw materials. Among the qNMR techniques, methods for 1H NMR and 19F NMR were developed. Appropriate solvents were chosen, and temperature, number of scans, acquisition time, and relaxation delay parameter settings were optimized. Maleic acid was chosen as the internal standard in 1H NMR, and the respective ch

APA, Harvard, Vancouver, ISO, and other styles

10

Zhang, Yu-Jing, and Shen-Ping Wu. "Therapeutic effect of Wendan Decoction combined with mosapride on gastroesophageal reflux disease after esophageal cancer surgery." World Journal of Clinical Cases 12, no. 13 (2024): 2194–200. http://dx.doi.org/10.12998/wjcc.v12.i13.2194.

Full text

Abstract:

BACKGROUND Gastroesophageal reflux disease (GERD) is a common complication of esophageal cancer surgery that can affect quality of life and increase the risk of esophageal stricture and anastomotic leakage. Wendan Decoction (WDD) is a traditional Chinese herbal formula used to treat various gastrointestinal disorders, such as gastritis, functional dyspepsia, and irritable bowel syndrome. Mosapride, a prokinetic agent, functions as a selective 5-hydroxytryptamine 4 agonist, enhancing gastrointestinal motility. AIM To evaluate the therapeutic effects of WDD combined with mosapride on GERD after

APA, Harvard, Vancouver, ISO, and other styles

11

Shimatani, Hidehiko, Yu Kojima, Makoto Kadowaki, et al. "A 5-HT4 agonist mosapride enhances rectorectal and rectoanal reflexes in guinea pigs." American Journal of Physiology-Gastrointestinal and Liver Physiology 285, no. 2 (2003): G389—G395. http://dx.doi.org/10.1152/ajpgi.00085.2003.

Full text

Abstract:

The rectal distension-evoked reflex rectal (R-R) contractions and internal anal sphincter (R-IAS) relaxations in guinea pigs were generated through the extrinsic sacral excitatory nerve pathway (pelvic nerves) and the intrinsic cholinergic excitatory and nitrergic inhibitory nerve pathways. The aim of the present study was to evaluate whether a prokinetic benzamide, mosapride, enhances the R-R and R-IAS reflexes mediated via 5-HT4 receptors in the guinea pig. The mechanical activities of the R and IAS were recorded with a balloon connected to a pressure transducer and a strain gauge force tran

APA, Harvard, Vancouver, ISO, and other styles

12

Anuradha R. Narwade and A. M. Mahale. "A Research on: Formulation and Evaluation of Sustained Release matrix Tablets." GSC Biological and Pharmaceutical Sciences 29, no. 2 (2024): 123–57. http://dx.doi.org/10.30574/gscbps.2024.29.2.0363.

Full text

Abstract:

The study focused on developing a sustained release matrix tablet of Mosapride Citrate to achieve prolonged therapeutic effects, reduce side effects, and improve patient compliance by minimizing dosing frequency. Mosapride Citrate, with a half-life of 2-3 hours, was used as a model drug. Matrix tablets were prepared using different viscosity grades of Eudragit through direct compression and evaluated. Results indicated that polymer matrices alone were insufficient for 8-hour sustained release, whereas a combination of Eudragit RS 100, Eudragit RL 100, and Eudragit E 100 provided effective sust

APA, Harvard, Vancouver, ISO, and other styles

13

Anuradha, R. Narwade, and M. Mahale A. "A Research on: Formulation and Evaluation of Sustained Release matrix Tablets." GSC Biological and Pharmaceutical Sciences 29, no. 2 (2024): 123–57. https://doi.org/10.5281/zenodo.14753754.

Full text

Abstract:

The study focused on developing a sustained release matrix tablet of Mosapride Citrate to achieve prolonged therapeutic effects, reduce side effects, and improve patient compliance by minimizing dosing frequency. Mosapride Citrate, with a half-life of 2-3 hours, was used as a model drug. Matrix tablets were prepared using different viscosity grades of Eudragit through direct compression and evaluated. Results indicated that polymer matrices alone were insufficient for 8-hour sustained release, whereas a combination of Eudragit RS 100, Eudragit RL 100, and Eudragit E 100 provided effective sust

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Mosapride enhances omeprazole pharmacokinetics,." Inpharma Weekly &NA;, no. 1492 (2005): 19. http://dx.doi.org/10.2165/00128413-200514920-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Korolkiewicz, Roman, and Jacek Sein-Anand. "Mosapride and Postoperative Ileus." Diseases of the Colon & Rectum 52, no. 4 (2009): 751–52. http://dx.doi.org/10.1007/dcr.0b013e3181a0dc27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kojima, Yu, Tadashi Nakagawa, Renta Katsui, Hisao Fujii, Yoshiyuki Nakajima, and Miyako Takaki. "A 5-HT4 agonist, mosapride, enhances intrinsic rectorectal and rectoanal reflexes after removal of extrinsic nerves in guinea pigs." American Journal of Physiology-Gastrointestinal and Liver Physiology 289, no. 2 (2005): G351—G360. http://dx.doi.org/10.1152/ajpgi.00532.2004.

Full text

Abstract:

Distension-evoked reflex of rectorectal (R-R) contractions and rectointernal anal sphincter (R-IAS) relaxations can be generated in guinea pigs through an extrinsic sacral excitatory neural pathway (pelvic nerves) as well as intrinsic cholinergic excitatory and nitrergic inhibitory pathways. The aim of the present study was to create intrinsic R-R and R-IAS reflex models by pithing (destruction of the lumbar and sacral cords; PITH) and to evaluate whether the prokinetic benzamide mosapride, a 5-HT4 receptor agonist, enhances these reflexes. The mechanical activities of the R-R and R-IAS were r

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Mosapride launched in first market." Inpharma Weekly &NA;, no. 1161 (1998): 22. http://dx.doi.org/10.2165/00128413-199811610-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kato, Shiro, and Yoshimi Hirokawa. "Synthesis of deuterated mosapride citrate." Journal of Labelled Compounds and Radiopharmaceuticals 36, no. 10 (1995): 927–32. http://dx.doi.org/10.1002/jlcr.2580361004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Jeon, Hye Kyung, Gwang Ha Kim, Moon Won Lee, Dong Chan Joo, and Bong Eun Lee. "Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease." Journal of Clinical Medicine 11, no. 7 (2022): 1965. http://dx.doi.org/10.3390/jcm11071965.

Full text

Abstract:

We aimed to evaluate whether adding a sustained-release (SR) formula of mosapride to proton-pump inhibitors (PPIs) would be more effective in controlling symptoms than PPI alone in patients with gastroesophageal reflux disease (GERD). Sixty patients with heartburn and/or regurgitation were randomly assigned to two groups: mosapride SR 15 mg combined with esomeprazole 20 mg once daily (ME group) and esomeprazole 20 mg once daily alone (E group). The primary endpoint was the complete-resolution rate of GERD symptoms after eight-week medication, and the secondary endpoints were the complete-resol

APA, Harvard, Vancouver, ISO, and other styles

20

Ye, Qing, Xiqun Chen, Hui Li, Yuqing Hu, Jie Zhou, and Chen Gao. "Efficacy of pyonex in the treatment of functional dyspepsia with mild to moderate depression." Traditional Medicine and Modern Medicine 03, no. 02 (2020): 93–99. http://dx.doi.org/10.1142/s257590002050007x.

Full text

Abstract:

Objective: To observe efficacy of pyonex in the treatment of functional dyspepsia (FD) with mild to moderate depression. Methods: 64 FD patients with mild to moderate depression were randomly divided into control group ([Formula: see text]) and test group ([Formula: see text]). The test group was given mosapride combined with pyonex, acupuncture at Neiguan, Shenmen, Zusanli and Taichong, and the control group was given mosapride combined with sertraline. The course of treatment was 4 weeks in both groups. The changes of LDQ and HAMD scores were compared between the two groups before and after

APA, Harvard, Vancouver, ISO, and other styles

21

Dou, Zhenyun, Zhou Xu, Qizheng Wang, et al. "Mosapride Citrate Combined with Divine Qu Disinfectant Oral Liquid for Children Function Dyspepsia and the Influence of Serum Factors." Journal of Healthcare Engineering 2022 (March 16, 2022): 1–5. http://dx.doi.org/10.1155/2022/3053277.

Full text

Abstract:

In order to investigate the efficacy of mosapril citrate combined with ShenQu Xiaoshi oral liquid in the treatment of children with functional dyspepsia and the effect on serum cytokines, 136 children with functional dyspepsia admitted from May 2017 to September 2020 were divided into 2 groups randomly, 68 cases in each group. The western medicine group was treated with mosapril citrate tablets, and the combined group was treated with Shenqu xiaoshi oral liquid on the basis of the western medicine group. The efficacy of patients was evaluated 14 days after treatment, and the safety, symptom sc

APA, Harvard, Vancouver, ISO, and other styles

22

Sun, Xiaohong, Lili Niu, Xiaoqin Li, Xiumei Lu, and Famei Li. "Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: Mosapride N-oxide and morpholine ring-opened mosapride by UPLC–ESI-MS/MS." Journal of Pharmaceutical and Biomedical Analysis 50, no. 1 (2009): 27–34. http://dx.doi.org/10.1016/j.jpba.2009.03.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sharma, A., BK Mohanti, A. Gogia, and P. Ganesan. "Protracted cisplatin-induced vomiting responding to mosapride." Indian Journal of Cancer 47, no. 1 (2010): 73. http://dx.doi.org/10.4103/0019-509x.58866.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bani Chander and Anish Sheth. "Mosapride in the Treatment of Gastrointestinal Disorders." Clinical Medicine Reviews in Therapeutics 2 (2010): 53–58. http://dx.doi.org/10.4137/cmrt.s1600.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Nagashima, Mamiko, Shinichi Okamura, Haruhisa Iizuka, et al. "Mosapride Citrate for Colonoscopy Preparation with Lavage." KITAKANTO Medical Journal 52, no. 2 (2002): 111–15. http://dx.doi.org/10.2974/kmj.52.111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sun, Xiao-Hong, Feng Man, Li-Yan Pang, et al. "Fungal biotransformation of mosapride by Cunninghamella elegans." Journal of Molecular Catalysis B: Enzymatic 59, no. 1-3 (2009): 82–89. http://dx.doi.org/10.1016/j.molcatb.2009.01.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hongo, Michio, Shigeru Harasawa, Tetsuya Mine, et al. "Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS)." Journal of Gastroenterology and Hepatology 27, no. 1 (2011): 62–68. http://dx.doi.org/10.1111/j.1440-1746.2011.06949.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Piyasena, INAP, and JAC Jayasinghe. "Mosapride (5HT4 agonist) in the treatment of blepharospasm." Ceylon Medical Journal 59, no. 1 (2014): 26. http://dx.doi.org/10.4038/cmj.v59i1.5527.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

WATANABE, Hideki, Yoshiaki TAKEUCHI, and Michio IMAWARI. "Mosapride Citrate Beneficially Affects Pharmacokinetic Parameters of Omeprazole." Showa University Journal of Medical Sciences 18, no. 1 (2006): 43–49. http://dx.doi.org/10.15369/sujms1989.18.43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

ElMeshad, Aliaa N., and Arwa S. El Hagrasy. "Characterization and Optimization of Orodispersible Mosapride Film Formulations." AAPS PharmSciTech 12, no. 4 (2011): 1384–92. http://dx.doi.org/10.1208/s12249-011-9713-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bang, Chang Seok, Jong Hyeok Kim, Gwang Ho Baik, et al. "Mosapride treatment for functional dyspepsia: A meta-analysis." Journal of Gastroenterology and Hepatology 30, no. 1 (2014): 28–42. http://dx.doi.org/10.1111/jgh.12662.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Zhang, Baoxi, Dezhi Yang, Li Zhang, et al. "Experimental and theoretical investigation of five mosapride forms." Journal of Molecular Structure 1319 (January 2025): 139299. http://dx.doi.org/10.1016/j.molstruc.2024.139299.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

YOSHIDA, Naoyuki. "Pharmacological effects of the gastroprokinetic agent mosapride citrate." Folia Pharmacologica Japonica 113, no. 5 (1999): 299–307. http://dx.doi.org/10.1254/fpj.113.299.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Mosapride: better glycaemic control in type 2 diabetes?" Inpharma Weekly &NA;, no. 1251 (2000): 6. http://dx.doi.org/10.2165/00128413-200012510-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

ARAI, Shozo, Makoto HARITANI, Hiroshi SAWADA, and Kumiko KIMURA. "Effect of mosapride on ruminal motility in cattle." Journal of Veterinary Medical Science 81, no. 7 (2019): 1017–20. http://dx.doi.org/10.1292/jvms.19-0196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

KUMAGAI, Y., T. FUJITA, M. OZAKI, Y. OHTANI, and M. MAJIMA. "Pharmacokinetics of mosapride citrate in patients with gastrectomy." Clinical Pharmacology & Therapeutics 77, no. 2 (2005): P51. http://dx.doi.org/10.1016/j.clpt.2004.12.085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kim, Hye Jin, Su Hyun Lee, Eun Ah Lim, and Jin-Seok Kim. "Formulation optimization of solid dispersion of mosapride hydrochloride." Archives of Pharmacal Research 34, no. 9 (2011): 1467–75. http://dx.doi.org/10.1007/s12272-011-0908-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Katoh, Takao, Hirokazu Saitoh, Norihiko Ohno, et al. "Drug Interaction Between Mosapride and Erythromycin Without Electrocardiographic Changes." Japanese Heart Journal 44, no. 2 (2003): 225–34. http://dx.doi.org/10.1536/jhj.44.225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Revanasiddappa, H. D., and M. A. Veena. "Spectrophotometric determination of mosapride in pure and pharmaceutical preparations." Eclética Química 32, no. 4 (2007): 71–75. http://dx.doi.org/10.1590/s0100-46702007000400010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

He, Mei, Takashi Ohrui, Takae Ebihara, Satoru Ebihara, Hidetada Sasaki, and Hiroyuki Arai. "MOSAPRIDE CITRATE PROLONGS SURVIVAL IN STROKE PATIENTS WITH GASTROSTOMY." Journal of the American Geriatrics Society 55, no. 1 (2007): 142–44. http://dx.doi.org/10.1111/j.1532-5415.2006.01026.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Koshino, Kenji, Kyoichi Adachi, Kenji Furuta, et al. "Effects of mosapride on esophageal functions and gastroesophageal reflux." Journal of Gastroenterology and Hepatology 25, no. 6 (2010): 1066–71. http://dx.doi.org/10.1111/j.1440-1746.2010.06280.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Toyomasu, Yoshitaka, Erito Mochiki, Hiroki Morita, et al. "Mosapride Citrate Improves Postoperative Ileus of Patients With Colectomy." Gastroenterology 140, no. 5 (2011): S—867. http://dx.doi.org/10.1016/s0016-5085(11)63602-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Chen, C. L., T. T. Liu, C. H. Yi, and W. C. Orr. "Effects of mosapride on esophageal secondary peristalsis in humans." Neurogastroenterology & Motility 23, no. 7 (2011): 606—e249. http://dx.doi.org/10.1111/j.1365-2982.2011.01714.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Komura, Makoto, Yutaka Kanamori, Yujiro Tanaka, et al. "Mosapride for gastroesophageal reflux disease in neurologically impaired patients." Pediatrics International 59, no. 3 (2016): 347–51. http://dx.doi.org/10.1111/ped.13144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Kuramoto, Takanori, Eijiro Morita, Mitsuyuki Murano, et al. "Usefulness of Mosapride Citrate As Preparation for Capsule Endoscopy." Gastrointestinal Endoscopy 69, no. 5 (2009): AB191. http://dx.doi.org/10.1016/j.gie.2009.03.406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Toyomasu, Yoshitaka, Erito Mochiki, Hiroki Morita, et al. "Mosapride Citrate Improves Postoperative Ileus of Patients with Colectomy." Journal of Gastrointestinal Surgery 15, no. 8 (2011): 1361–67. http://dx.doi.org/10.1007/s11605-011-1567-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Revanasiddappa, Hosakere Doddarevanna, and M. A. Veena. "Spectrophotometric determination of mosapride in pure and pharmaceutical preparations." Ecletica Quimica 32, no. 4 (2007): 71–75. http://dx.doi.org/10.26850/1678-4618eqj.v32.4.2007.p71-75.

Full text

Abstract:

Two simple and sensitive spectrophotometric methods (M 1 and M 2 ) for the determination ofmosapride in pure and in pharmaceutical preparations are described. These methods are based on theinteraction of diazotized mosapride (MSP) couples with chromotropic acid (CTA) [M 1 ] in alkalinemedium and diphenylamine (DPA) [M 2 ] in acidic medium. The resulting azo-dyes exhibit maximumabsorption at 560 nm and at 540 nm for methods M 1 and M 2 , respectively. All variables were studiedin order to optimize the reaction conditions. No interferences were observed from excipients, and thevalidity of the ea

APA, Harvard, Vancouver, ISO, and other styles

48

Yi, Tingting. "Development and evaluation of mosapride citrate orally disintegrating tablets for dogs." Ciência Rural 46, no. 11 (2016): 2064–69. http://dx.doi.org/10.1590/0103-8478cr20160402.

Full text

Abstract:

ABSTRACT: The purpose of the study was to prepare orally disintegrating tablets (ODTs) of mosapride citrate for dogs with fast disintegration and low cost. The ODTs were developed by varying the components and the ratio of excipients. A direct compression method was used. The properties of the ODTs, including hardness, friability, active ingredient content, and in vitro disintegration time, were investigated, and an economic analysis of the formulations was performed. For all formulations, friability was less than 1%, and the hardness varied from 37.69±4.08 to 48.73±5.62 N, which indicated tha

APA, Harvard, Vancouver, ISO, and other styles

49

Wu, Xiao, Yi Zhou, Guang Chen, et al. "Effect of Electroacupuncture with Different Current Intensities on the Serum Metabolomics of Functional Constipation." Evidence-Based Complementary and Alternative Medicine 2023 (July 18, 2023): 1–10. http://dx.doi.org/10.1155/2023/9693390.

Full text

Abstract:

Objective. The aim of the study is to investigate the serum metabolomics of electroacupuncture (EA) with different current intensities in the treatment of functional constipation (FC). Methods. The total number of FC patients was 19, (7, 6, 6, in the low current intensity group (LCI), high current intensity group (HCI), and mosapride citrate tablet control group (MC), respectively). Patients in the EA groups received 16 sessions of acupuncture treatments. Patients in the MC group were orally administered 5 mg mosapride citrate tablets 3 times daily, and serum samples were collected from the pa

APA, Harvard, Vancouver, ISO, and other styles

50

Erin L. Toto and Darren M. Brenner. "The Efficacy of Mosapride for the Treatment of Functional Dyspepsia." Clinical Medicine Reviews in Therapeutics 2 (2010): 137–44. http://dx.doi.org/10.4137/cmrt.s4763.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!